Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2024)
Roivant Sciences (ROIV) posted Net Income towards Common Stockholders of $373.2 million for Q4 2024, up 966.2% on a QoQ basis from -$43.1 million in Q3 2024, and up 264.66% year-over-year from $102.3 million in Q1 2024.
Roivant Sciences (ROIV) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
Roivant Sciences' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at $373.2 million for Q4 2024.
- Quarterly Net Income towards Common Stockholders rose 264.66% year-over-year to $373.2 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $373.2 million (up 306.6% YoY) and the FY2025 annual result came in at $373.2 million, up 218.42% from the prior year.
- Net Income towards Common Stockholders was $373.2 million for Q4 2024 at Roivant Sciences, up from -$43.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $373.2 million in Q4 2024 and bottomed at -$1.1 billion in Q4 2022.
- A 5-year average of -$216.2 million and a median of -$225.6 million in 2021 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 1167.12% — and 2024, when it surged 264.66%.
- Roivant Sciences' Net Income towards Common Stockholders stood at -$275.6 million in 2020, then plunged by 129.61% to -$632.8 million in 2021, then sank by 66.66% to -$1.1 billion in 2022, then jumped by 78.51% to -$226.6 million in 2023, then jumped by 264.66% to $373.2 million in 2024.
- Business Quant data shows ROIV's Net Income towards Common Stockholders at $373.2 million in Q4 2024, -$43.1 million in Q3 2024, and $89.1 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Roivant Sciences | 24.27 Bn | 24.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 373.19 Mn |
| Sep 30, 2024 | -43.08 Mn |
| Jun 30, 2024 | 89.09 Mn |
| Dec 31, 2023 | -226.64 Mn |
| Sep 30, 2023 | -86.10 Mn |
| Jun 30, 2023 | -327.85 Mn |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -315.92 Mn |
| Jun 30, 2022 | -353.78 Mn |
| Dec 31, 2021 | -632.80 Mn |
| Sep 30, 2021 | -225.64 Mn |
| Jun 30, 2021 | -101.08 Mn |
| Dec 31, 2020 | -275.60 Mn |
| Sep 30, 2020 | -53.50 Mn |
| Jun 30, 2020 | -7.98 Mn |